Human Cytochrome P450 2J2,CYP2J2 ELI

A cytochrome P450 monooxygenase involved in the metabolism of polyunsaturated fatty acids (PUFA) in the cardiovascular system (PubMed:8631948, PubMed:19965576).

Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:8631948, PubMed:19965576).

Catalyzes the epoxidation of double bonds of PUFA (PubMed:8631948, PubMed:19965576).

Converts arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (EpETrE), likely playing a major role in the epoxidation of endogenous cardiac arachidonic acid pools (PubMed:8631948).

In endothelial cells, participates in eicosanoids metabolism by converting hydroperoxide species into hydroxy epoxy metabolites.

In combination with 15-lipoxygenase metabolizes arachidonic acid and converts hydroperoxyicosatetraenoates (HpETEs) into hydroxy epoxy eicosatrienoates (HEETs), which are precursors of vasodilatory trihydroxyicosatrienoic acids (THETAs).

This hydroperoxide isomerase activity is NADPH- and O2-independent (PubMed:19737933).

Catalyzes the monooxygenation of a various xenobiotics, such as danazol, amiodarone, terfenadine, astemizole, thioridazine, tamoxifen, cyclosporin A and nabumetone (PubMed:19923256).

Catalyzes hydroxylation of the anthelmintics albendazole and fenbendazole (PubMed:23959307).

Catalyzes the sulfoxidation of fenbedazole (PubMed:19923256).

{ECO:0000269|PubMed:19737933, ECO:0000269|PubMed:19923256, ECO:0000269|PubMed:19965576, ECO:0000269|PubMed:23959307, ECO:0000269|PubMed:8631948}.